Publication Author: Urban_Nicole

• Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

  Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW. Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):

  rakerr2

  November 1, 2012

• Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling.

  Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban N, Buist DS. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. Gynecol Oncol. 2012 Aug;126(2):229-35. doi: 10.1016/j.ygyno.2012.04.046. Epub 201

  rakerr2

  August 1, 2012

• Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening.

  Drescher CW, Hawley S, Thorpe JD, Marticke S, McIntosh M, Gambhir SS, Urban N. Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila). 2012 Aug;5(8):1015-

  rakerr2

  August 1, 2012

• Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

  Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE, Urban N. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012 Apr;125(1):65-9. Epub 2011

  rakerr2

  April 1, 2012

• An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.

  Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O’Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, Drescher CW, Swisher EM, Tewari M. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family

  rakerr2

  January 1, 2012

• Designing early detection programs for ovarian cancer.

  Urban N. Designing early detection programs for ovarian cancer. Ann Oncol. 2011 Dec;22 Suppl 8:viii6-viii18.

  rakerr2

  December 1, 2011

• Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

  Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O’Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW. Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst. 2011 Nov

  rakerr2

  November 2, 2011

• Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.

  Miller CP, Urban N, Blau CA. Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors. Anticancer Res. 2011 Apr;31(4):1189-95.

  rakerr2

  April 1, 2011

• Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.

  Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Möller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PL

  rakerr2

  January 14, 2011

• Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.

  Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK 3rd, Urban N, Drescher C, Hemminki A, Fender P, Lieber A. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011 Jan;17(1)

  rakerr2

  January 1, 2011